


Envonalkib

Cat. No.:	HY-145566		
CAS No.:	1621519-26-3		
Molecular Formula:	C ₂₄ H ₂₆ Cl ₂ FN ₅ O ₂		
Molecular Weight:	506.4		
Target:	Anaplastic lymphoma kinase (ALK)		
Pathway:	Protein Tyrosine Kinase/RTK		
Storage:	Powder	-20°C	3 years
		4°C	2 years
	In solvent	-80°C	6 months
		-20°C	1 month



SOLVENT & SOLUBILITY

In Vitro

DMSO : 100 mg/mL (197.47 mM; Need ultrasonic)

Concentration	Mass		
	1 mg	5 mg	10 mg
1 mM	1.9747 mL	9.8736 mL	19.7472 mL
5 mM	0.3949 mL	1.9747 mL	3.9494 mL
10 mM	0.1975 mL	0.9874 mL	1.9747 mL

Please refer to the solubility information to select the appropriate solvent.

BIOLOGICAL ACTIVITY

Description

Envonalkib is a potent and orally active inhibitor of ALK, with IC₅₀s of 1.96 nM, 35.1 nM, and 61.3 nM for WT and mutated L1196M and G1269S-ALK. Envonalkib can be used for the research of non-small cell lung cancer^[1].

IC₅₀ & Target

IC₅₀: 1.96 nM (WT-ALK), 35.1 nM (mutated L1196M-ALK), 61.3 nM (mutated G1269S-ALK)^[1]

In Vivo

Envonalkib (formula I) (12.5-25 mg/kg; p.o. once daily for 14 days) inhibits the growth of human non-small cell lung cancer NCI-H2228 nude mice xenografts^[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES

[1]. Feng G, et, al. Pyridine-substituted 2-aminopyridine protein kinase inhibitors. WO2016015676A1.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA